EDIT (Editas Medicine) Construction In Progress: $0.00 Mil (As of Mar. 2026)


EDIT Editas Medicine Inc EDIT
51 GF Score
Price $2.86
GF Value $1.92
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine Construction In Progress?

Editas Medicine EDIT +1.96% 51 Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.92 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Editas Medicine's quarterly construction in progress declined from Sep. 2025 ($0.08 Mil) to Dec. 2025 ($0.00 Mil) but then stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Editas Medicine's annual construction in progress declined from Dec. 2023 ($2.06 Mil) to Dec. 2024 ($0.83 Mil) and declined from Dec. 2024 ($0.83 Mil) to Dec. 2025 ($0.00 Mil).

Editas Medicine Construction In Progress Historical Data

* Premium members only.

The historical data trend for Editas Medicine's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine Construction In Progress Chart

Editas Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.53 1.57 2.06 0.83 0.00

Editas Medicine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.00 0.08 0.00 0.00
EDIT
51GF Score
Editas Medicine Inc EDIT
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Editas Medicine Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Editas Medicine (EDIT) has a Construction In Progress of $0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Editas Medicine and its competitors.
Is Editas Medicine's Construction In Progress too high?
Editas Medicine's current Construction In Progress is $0.00 Mil. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Construction In Progress compare to PRTA and XOMA?
Editas Medicine's Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Editas Medicine and its competitors. Editas Medicine's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $2.86 — trading 48.7% above its estimated fair value. The current Construction In Progress is $0.00 Mil. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $2.86 is trading 48.7% above its estimated GF Value™ of $1.92. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • Construction In Progress: $0.00 Mil
  • GF Value™: $1.92 vs. price of $2.86 (48.7% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score

Get the complete analysis for EDIT

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.86
Price
$1.92
GF Value